About us.

Tactiva Therapeutics is an Immuno-Oncology Company Utilizing an Innovative Approach to Adoptive Cell Therapy.

Matthew E. Colpoys

Chief Executive Officer

Matthew has invested much of his 30-year career building relationships within the scientific, academic, corporate, and investor communities.

He is an accomplished executive who has held numerous leadership positions in the biopharma and med tech industries. He spent the early part of his career focused on commercial activities, including contributing to the successful launches of Activase®, a recombinant tissue plasminogen activator (rtPA), and Nutropin® human growth hormone (hGH) while working at Genentech. He then helped to build the US endocrine marketing organization at Pharmacia. Following those accomplishments, he established sales organizations and directed commercial activities at Neurex, Elan, and Insmed.

Richard C. Koya, MD, PhD

Chief Scientific Officer

Dr. Koya, M.D., PhD. is the Director of the Vector Development and Production Facility and the Associate Director of the Center for Immunotherapy at Roswell Park Cancer Institute (RPCI). He is also  Associate Professor of oncology and  member of the Tumor Immunology and Immunotherapy CCSG Program at RPCI.  Before joining RPCI, Dr. Koya was previously an assistant professor in the Department of Surgery, Division of Surgical Oncology,  UCLA, with research focus in cancer gene therapy and immunology.

At RPCI, he maintains an active research program focused on finding new and efficacious therapies for cancer based on immunotherapy and gene therapy, overseeing many scientists in his research lab. Dr. Koya is an author of many high-impact publications in the field of cancer research, and he currently leads a National Institutes of Health (NIH) prospective clinical trials program based on  immune modulator/enhancer, T Cell Receptor-engineered T cell transfer for metastatic cancer patients. He also serves as a peer reviewer for various scientific journals in the field of cancer research and immunology and as reviewer for grants in scientific review study sections of the NIH and National Cancer Institute (NCI).

Dr. Koya has received many awards; among them are the Scholar Award from the Ministry of Education and Culture of Japan, the Ito Foundation Award, the Nickel-V Foundation Award, and the STOP CANCER Award.

Kunle Odunsi, MD, PhD, FRCOG, FACOG

Chief Medical Officer

Kunle Odunsi, MD PhD is the Deputy Director of  Roswell Park Cancer Institute (RPCI). He is also Professor and Chair of the Department of Gynecologic Oncology, the M. Steven Piver Endowed Professor of Gynecologic Oncology at RPCI, and the Executive Director of the Center for Immunotherapy at RPCI.

He maintains an active research program focused on understanding the mechanisms of immune recognition and tolerance in ovarian cancer, as well as the translation of the findings to clinical immunotherapy trials. Dr. Odunsi has implemented protocols for multi-institutional immunotherapy clinical trials under the National Cancer Institute (NCI) Cancer Immunotherapy Network (CITN) and the Cancer Vaccine Collaborative (CVC) program of the Cancer Research Institute and Ludwig Institute for Cancer Research.

He is the principal investigator of an NCI-funded, multi-million-dollar Specialized Program of Research Excellence (SPORE) in ovarian cancer, and he is the principal investigator of a multi-million-dollar grant from the New York State Stem Cell Science program (NYSTEM) to pioneer a novel strategy of reprogramming human mature T cells and hematopoietic stem cells for generating sustained attack against ovarian cancer in patients.

Dr. Odunsi has authored or co-authored more than 280 journal publications or book chapters. He is co-chair of the NCI Ovarian Cancer Task Force of the Gynecological Cancer Steering Committee, and was a member of the Institute of Medicine’s Committee on the State of the Science in Ovarian Cancer Research. He has served on several scientific review study sections of the National Institutes of Health (NIH).  He is on the editorial boards of BMC Cancer, the Journal for the Immunotherapy of Cancer, Gynecologic Oncology, and Cancer Immunology Research.

Dr. Odunsi is the recipient of numerous awards and honors, including the Anna-Marie Kellen Clinical Investigator Award from the Cancer Research Institute; Achievement in Healthcare Award from D’Youville College, Buffalo; and the RPCI Thomas B. Tomasi Hope Award for significant advances in the fight against cancer and bringing hope to cancer patients.

 

 

 

Program history.

The technology used by Tactiva Therapeutics is licensed from Roswell Park Cancer Institute (RPCI). To date, the program has received $23 million in grant support from the National Cancer Institute’s Specialized Programs of Research Excellence (SPORE) Grant and NY Stem Cell Science program (NYSTEM).

Each of these grants supports clinical trials with our proprietary technology through the Center for Immunotherapy at RPCI in Buffalo, New York. Learn more about our adoptive cell therapy »

Get in touch with us.

Have a question? Want to speak with someone from our team?